Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 6:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 60 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Open-label Abatacept Clear all
Terminated Phase 2 Interventional Results available

Safety Study of Abatacept to Treat Refractory Sarcoidosis

NCT00739960
View directory record Official record
Conditions
Sarcoidosis
Interventions
Abatacept
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 1, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy Participants

NCT05981976
View directory record Official record
Conditions
Healthy Participants
Interventions
Abatacept
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
3
States / cities
Cypress, California • Miami, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 1, 2026, 6:55 PM EDT
Completed Phase 1 Interventional

Study on the Safety of Abatacept in Relapsing Polychondritis

NCT01272856
View directory record Official record
Conditions
Relapsing Polychondritis
Interventions
Abatacept
Drug
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 1, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

Phase IIIB Subcutaneous Abatacept Monotherapy Study

NCT00547521
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
abatacept, Methotrexate (MTX)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
15
States / cities
Huntsville, Alabama • Mobile, Alabama • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Oct 1, 2026, 6:55 PM EDT
Completed Not applicable Interventional

Belatacept in Renal Transplantation With Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores

NCT01496417
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Belatacept
Drug
Lead sponsor
University of Maryland
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 1, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes

NCT03714022
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
South Miami, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 1, 2026, 6:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy of Belatacept in Reducing DSA

NCT02078193
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Belatacept
Drug
Lead sponsor
East Carolina University
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 1, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone

NCT00119678
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Abatacept, Placebo, Prednisone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
12
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 1, 2026, 6:55 PM EDT
Completed Phase 2Phase 3 Interventional

Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage

NCT01333878
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Subcutaneous Abatacept
Biological
Lead sponsor
Orrin M Troum, M.D. and Medical Associates
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 1, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis

NCT02161406
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Dinesh Khanna, MD, MS
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
23
States / cities
Los Angeles, California • Redwood City, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 1, 2026, 6:55 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

NCT04877288
View directory record Official record
Conditions
Renal Allograft Recipients
Interventions
Belatacept, Tacrolimus, Cyclosporine A, Mycophenolate Mofetil, Enteric Coated Mycophenolate Sodium, Corticosteroids
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years to 17 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 1, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

Belatacept Pharmacokinetic Trial in Renal Transplantation

NCT00578448
View directory record Official record
Conditions
Renal Transplantation
Interventions
Belatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Springfield, Massachusetts • Detriot, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 1, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

NCT03086343
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Abatacept, Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion), Upadacitinib, Placebo for upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
44
States / cities
Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 1, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome

NCT02915159
View directory record Official record
Conditions
Sjogrens Disease
Interventions
Abatacept, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
19
States / cities
Fullerton, California • Riverside, California • Lakewood, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 1, 2026, 6:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis

NCT00468208
View directory record Official record
Conditions
Wegener's Granulomatosis
Interventions
Abatacept
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
15 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 1, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis

NCT00095173
View directory record Official record
Conditions
Juvenile Rheumatoid Arthritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years to 17 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
10
States / cities
Omaha, Nebraska • Livingston, New Jersey • New Hyde Park, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 1, 2026, 6:55 PM EDT
Completed Phase 3 Interventional

Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)

NCT02108860
View directory record Official record
Conditions
Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis, Wegener's Granulomatosis, ANCA-Associated Vasculitis
Interventions
Abatacept, placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
15 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Tampa, Florida • Kansas City, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 1, 2026, 6:55 PM EDT
Completed Phase 4 Interventional Results available

Abatacept in Juvenile Dermatomyositis

NCT02594735
View directory record Official record
Conditions
Dermatomyositis
Interventions
Abatacept
Drug
Lead sponsor
George Washington University
Other
Eligibility
7 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Oct 1, 2026, 6:55 PM EDT
Not listed Phase 4 Interventional

Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression

NCT01875224
View directory record Official record
Conditions
New Onset Diabetes After Transplant, Kidney Transplantation
Interventions
Belatacept, Tacrolimus
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Oct 1, 2026, 6:55 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Abatacept in Patients With Active Crohn's Disease

NCT00406653
View directory record Official record
Conditions
Crohn's Disease
Interventions
abatacept, placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
37
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Oct 1, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis

NCT00095147
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept (ABA) + Methotrexate (MTX), double-blind (DB), Infliximab (INF) + MTX, DB, Placebo (PLA) + MTX, DB, PLA + MTX switched to ABA+ MTX, DB, ABA, open-label (OL)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
19
States / cities
Huntsville, Alabama • Denver, Colorado • Boca Raton, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 1, 2026, 6:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy

NCT00886795
View directory record Official record
Conditions
Urticaria
Interventions
abatacept (Orencia ®)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 1, 2026, 6:55 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis

NCT03882008
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 1, 2026, 6:55 PM EDT
Recruiting Phase 1 Interventional

Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

NCT06008808
View directory record Official record
Conditions
Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease
Interventions
Ruxolitinib, Abatacept
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 1, 2026, 6:55 PM EDT